Clinical Cases Podcast Series-FREE NO CME-Opioid + Benzodiazepine Tapering How-To Guide

Opioid + Benzodiazepine Tapering How-To Guide

Pdf Summary

This toolkit provides practical guidance for tapering opioids and, when co-prescribed, benzodiazepines, emphasizing shared decision-making and patient support. It recommends structured tapering frameworks (e.g., BRAVO and the HHS clinician guide) and outlines communication steps to improve success: explain individualized reasons for tapering, negotiate the plan (rate and which opioid first), manage difficult conversations to preserve the therapeutic alliance, and explicitly pledge ongoing support with more frequent visits and check-ins.<br /><br />A checklist is organized by taper phases. Before tapering, clinicians should identify appropriate candidates (e.g., lack of benefit, adverse effects, aberrant behavior, risks outweigh benefits), assess readiness and substance use disorder, provide naloxone, and implement non-opioid pain and behavioral supports. The plan should specify which opioid to taper first, taper duration, a contingency plan for pain/withdrawal, start and estimated completion dates, and confirm naloxone access.<br /><br />For initiation, the toolkit reviews opioid dose calculations including morphine equivalent daily dose (MEDD) using conversion factors, and cautions to reduce doses when rotating opioids due to incomplete cross-tolerance. Suggested taper rates include a slow taper (reduce total daily MEDD by 5–10% every 2–4 weeks, preferred for most patients and long-acting opioids) and a rapid taper (5–15% per week for imminent safety concerns, often with short-acting opioids). Special guidance is included for transitioning off transdermal fentanyl to oral long-acting opioids before tapering.<br /><br />During tapering, clinicians should increase monitoring (every 1–4 weeks plus interim contact), reassess goals, pain/function, and withdrawal, and individualize by slowing or pausing (without increasing the dose). A table lists common withdrawal symptoms and PRN medications (e.g., clonidine for autonomic symptoms, hydroxyzine for anxiety, NSAIDs/acetaminophen for myalgias, trazodone for sleep, antiemetics, antispasmodics, loperamide).<br /><br />The toolkit also describes buprenorphine microinduction (small initial doses while continuing full agonists, then escalating to therapeutic doses and stopping/tapering the full agonist) for candidates such as OUD, prior failed tapers, hyperalgesia, or fear of withdrawal, with a sample day-by-day schedule.<br /><br />Finally, it addresses deprescribing indications and documentation using a benefit-risk framework, and advises that when opioids and benzodiazepines are co-prescribed, clinicians should discuss harms and plan to taper both—typically tapering opioids first, then benzodiazepines.

Keywords

opioid tapering

benzodiazepine deprescribing

shared decision-making

morphine equivalent daily dose

BRAVO framework

HHS clinician guide

withdrawal management

buprenorphine microinduction

naloxone

therapeutic alliance